HRMY Stock Analysis: "Wakix Momentum" Revisited — Billion-Dollar Year or Orexin Reckoning?

When we last looked at Harmony Biosciences in December, the question was whether a genuinely great commercial story — WAKIX, growing near 30% — was papering over an uncertain pipeline. Eight months later, Harmony has answered half of that question emphatically. The other half got harder on August 5, and not because of anything Harmony did.

The quarter

Second-quarter numbers, reported August 4, were a record on nearly every line. WAKIX net revenue of $261.3 million, up 30% from $200.5 million a year ago. Net income of $75.4 million — $1.28 in diluted EPS. Cash, equivalents, and investments of $962.5 million. An average of roughly 8,950 patients on therapy, up about 450 in the quarter — the second-best quarterly patient add in the drug's history. Management reiterated full-year guidance of $1.0 to $1.04 billion, which would make 2026 WAKIX's first billion-dollar year.

For context on how fast this has compounded: when we wrote in December, the trailing quarter was $239.5 million and the patient base was about 8,100. CEO Jeffrey Dayno credited "sustained WAKIX demand" and said the company intends to keep "aggressively advancing our pipeline." On the evidence, both halves of that sentence are currently true.

The pipeline answer

Our December concern was that Harmony's future beyond pitolisant was mostly a collection of question marks — R&D spending had jumped 117% while the lead expansion asset (ZYN002 in Fragile X) had already stumbled. The Q2 update is the first time the pipeline story has come with actual human data attached.

BP-205, Harmony's own orexin-2 receptor agonist, produced Phase 1 single-ascending-dose results that read cleanly: peak concentration in 30 to 75 minutes, supporting rapid onset; a roughly 25-hour half-life, supporting once-daily dosing; no serious or severe adverse events, with headache (~10%), fatigue (~4%), and diarrhea (~3%) the most common complaints and no cardiovascular, hepatic, or visual signals. Multiple-ascending-dose data are expected in Q4 2026, a Phase 1b in sleep-deprived volunteers starts this quarter with data in early 2027, and Phase 2 studies across CNS indications are slated for mid-2027.

Behind it, the rest of the calendar has firmed up: the FDA accepted the pitolisant gastro-resistant NDA in July with a PDUFA date of April 1, 2027; Phase 3 data for the higher-dose formulation are expected in 2027; TEMPO (WAKIX in Prader-Willi) reads out topline in mid-2027; and EPX-100 Phase 3 data are due in the first half of 2027. That is a real pipeline with real dates — the thing we said was missing.

Then Takeda showed up

On August 5 — one day after Harmony's print — the FDA approved Takeda's ORZEYFUL (oveporexton), the first orexin-2 receptor agonist, for narcolepsy type 1. The Phase 3 FirstLight and RadiantLight studies showed improvements across the symptom range of NT1, including daytime sleepiness and cataplexy. Launch awaits DEA scheduling, expected within roughly 90 days, which puts the drug in specialty pharmacies around the fourth quarter.

Be precise about what this is and isn't. It is the first mechanism-level challenge to WAKIX's franchise in its most important population: orexin agonism replaces the missing signal in NT1 rather than modulating around it, and the efficacy bar it sets is high. It is not a clean sweep: oveporexton's label covers NT1 only, WAKIX is prescribed across a broader narcolepsy population, and the new drug carries a notable tolerability caveat — insomnia in 55% to 60% of patients versus 1% on placebo, plus twice-daily dosing. Harmony's own BP-205 pitch — once-daily, clean early tolerability — is aimed squarely at those seams. But BP-205 is in Phase 1. Takeda is launching. The gap between those two sentences is measured in years.

The tape

The market has processed this sequence about how you would expect. The stock jumped roughly 9% after the August 4 report, then cooled as the approval landed; it closed Friday (August 14) at $38.12, up a modest 2% year-to-date, within a 52-week range of $25.52 to $40.87. Worth noting against our December piece: the stock was around $33 then, and we flagged the mid-$30s as where the easy re-rating likely stalled. It has pushed through that — on fundamentals, with a competitive overhang attached.

What we're watching

WAKIX patient adds in Q4 and beyond, once ORZEYFUL is actually in pharmacies — scripts, not narratives, will show whether NT1 switching is real. BP-205 multiple-dose data in Q4, the first checkpoint on whether the once-daily, cleaner-tolerability profile survives contact with more exposure. The April 1, 2027 PDUFA for pitolisant GR. And what Harmony does with $962 million in cash against a rivalry that just went commercial — that balance sheet is big enough to buy optionality, and this is the moment to spend some.

Methodology & sources

Financial and pipeline figures are from Harmony's Q2 2026 results release of August 4, 2026 (GlobeNewswire). ORZEYFUL approval details, study names, insomnia rates, and launch timing are from Takeda's August 5, 2026 announcement. Price and performance data are from Interactive Brokers market data as of Friday's close, August 14, 2026. Prior-coverage comparisons reference our December 2, 2025 HRMY analysis.

Small Cap Newsroom is a research publication, not an investment adviser, and nothing here is investment advice or a recommendation to buy or sell any security. Approvals do not predict returns. The author may hold positions in securities mentioned. Do your own research.

Editor’s note (September 2026): This piece predates SCN’s current editorial standards and is retained as published. See how SCN works.

SCN editorial — independent commentary for information only, not investment advice.